Editor's note

This ExpertREACT article was originally published on 7 October 2012. Pipeline statuses, trial data and company positions described reflect the state of knowledge at that date.

Approximately 90 projects in clinical development

VacZine Analytics' latest analysis recorded approximately 90 vaccine projects in clinical development across Phases I, II and III. This figure excluded global initiative programmes targeting tuberculosis, malaria and pandemic influenza, as well as therapeutic vaccine approaches for non-communicable diseases. Analysis of IP and company reporting also suggested continued significant investment at preclinical stages, indicating R&D momentum remained high. The majority of pipeline projects fell within the "novel adult" category, targeting nosocomial or hospital-acquired infections such as Clostridium difficile (Phase II), Pseudomonas aeruginosa (Phase II/III) and Staphylococcus aureus (Phase II).

Montana-based LigoCyte's norovirus VLP vaccine entered a Phase II study (NCT01609257) in 2012 and attracted a $60m milestone payment from Takeda's global vaccine division. Takeda was already investigating Haemophilus influenzae type b (Hib) and Sabin-inactivated poliovirus (s-IPV) programmes. Astellas Pharma had separately in-licensed Vical's therapeutic CMV vaccine (Transvax), with both Japanese company moves signifying a growing willingness to invest in programmes that did not meet the high threshold criteria of incumbent Western players.

Pipeline size (Autumn 2012)
~90
Vaccine projects in clinical development (Phases I-III), excluding global initiatives and pandemic flu

Insect-borne and endemic diseases expanding

Insect-borne and endemic diseases contributed a significant and growing number of projects to the pipeline. Dengue, Enterovirus-71 and other tropical diseases were increasingly represented as both government and private sector interest in vaccines for developing and travel markets continued to grow. Two therapeutic Candida vaccine candidates - Pevion Biotech's PEV7 and Novadigm's NDV-3 - were advancing for recurrent vulvovaginal candidiasis (RVVC), an area with strong unmet need that could establish a new over-the-counter vaccine concept unique in the field.